Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ETAPA I: Evaluation of Tumor Associated P30-Peptide Antigen I; A Pilot Trial of Peptide-based Tumor Associated Antigen Vaccines in Newly Diagnosed, Unmethylated, and Untreated Glioblastoma (GBM)

NCT05283109 is registered in ClinicalTrials.gov with Mustafa Khasraw, MBChB, MD, FRCP, FRACP as lead sponsor.

NCT NCT05283109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05283109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ETAPA I: Evaluation of Tumor Associated P30-Peptide Antigen I; A Pilot Trial of Peptide-based Tumor Associated Antigen Vaccines in Newly Diagnosed, Unmethylated, and Untreated Glioblastoma (GBM)
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 30, 2023
Completion date
February 28, 2028
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, malignant